Plain-English translation of NCT06170970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that promotes wakefulness, to see if it can help reduce the severe fatigue that many people with multiple sclerosis experience. Fatigue affects up to 90% of MS patients and current treatments don't work well for everyone. This study will measure whether the medication improves fatigue, especially in people who also struggle with daytime sleepiness.
Fatigue is one of the most disabling symptoms of MS, but treatments available today—especially for patients who also have excessive daytime sleepiness—have shown limited success. Researchers want to test whether this medication could be a better option for this specific group of MS patients.
You likely qualify if…
You likely don't qualify if…
You would participate in two four-week treatment periods separated by a one-week break. In one period you'd take the medication; in the other you'd take a placebo (a pill with no active ingredient). Before starting, there's a 10-day lead-in period. Throughout the study, you'd complete questionnaires about your fatigue and use a smartphone app that tracks fatigue through typing patterns in real time. The study uses a 'double-blind' design, meaning neither you nor the researchers will know which period has the medication versus placebo until the study ends.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States